Long-term iloprost infusion therapy for
โ
Jose De La Mata; Miguel A. Gomez-Sanchez; Mercedes Aranzana; Juan J. Gomez-Reino
๐
Article
๐
1994
๐
John Wiley and Sons
๐
English
โ 613 KB
Objective. To determine the effects of short-term, maximum-tolerated-dose and long-term, optimum-dose iloprost treatment of severe pulmonary hypertension associated with systemic sclerosis (SSc) and the primary antiphospholipid syndrome (APS). Methods. Three patients with SSc and 2 with APS who had